{
  "id": "cachexia-1625389-bb04eed9c6d9fc4d",
  "slug": "cachexia",
  "title": "Cachexia",
  "qid": "Q14893651",
  "lead": "Cachexia ( ) is a syndrome that occurs in people with certain illnesses, causing muscle loss that cannot be fully reversed with improved nutrition. It most commonly occurs in cases of cancer, congestive heart failure, chronic obstructive pulmonary disease, chronic kidney disease, and AIDS. These conditions change how the body handles inflammation, metabolism, and brain signaling. This can lead to muscle loss and other harmful changes to body composition over time. Unlike weight loss from inadequate caloric intake, cachexia mainly causes muscle loss and can happen with or without fat loss. Diagnosis of cachexia is difficult because there are no clear guidelines, and its occurrence varies from one affected person to the next. Like malnutrition, cachexia can lead to worse health outcomes and lower quality of life. The prognosis of patients with cachexia varies depending on the type and severity of the underlying illness, but is typically poor, especially with patients in late stages of disease. Cachexia can improve significantly with effective treatment of the underlying illness, but symptomatic treatment approaches such as nutritional therapy and exercise typically do not result in reversal of the syndrome, and have very limited benefit in advanced cases of cachexia.",
  "body": "Cachexia ( ) is a syndrome that occurs in people with certain illnesses, causing muscle loss that cannot be fully reversed with improved nutrition. It most commonly occurs in cases of cancer, congestive heart failure, chronic obstructive pulmonary disease, chronic kidney disease, and AIDS. These conditions change how the body handles inflammation, metabolism, and brain signaling. This can lead to muscle loss and other harmful changes to body composition over time. Unlike weight loss from inadequate caloric intake, cachexia mainly causes muscle loss and can happen with or without fat loss. Diagnosis of cachexia is difficult because there are no clear guidelines, and its occurrence varies from one affected person to the next. Like malnutrition, cachexia can lead to worse health outcomes and lower quality of life. The prognosis of patients with cachexia varies depending on the type and severity of the underlying illness, but is typically poor, especially with patients in late stages of disease. Cachexia can improve significantly with effective treatment of the underlying illness, but symptomatic treatment approaches such as nutritional therapy and exercise typically do not result in reversal of the syndrome, and have very limited benefit in advanced cases of cachexia. ==Definition== Cachexia is hard to define because it often happens alongside malnutrition and sarcopenia. Since there are no clear rules separating these conditions, experts continue working to agree on definitions to help treat these nutrition-related problems. In the past, cachexia was described as \"a complex metabolic syndrome associated with underlying illness and characterized by loss of muscle with or without loss of fat mass.\" In 2011, experts updated this definition, saying cachexia is \"a multifactorial syndrome defined by an ongoing loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment.\" They also suggested breaking it into three stages: pre-cachexia, cachexia, and refractory cachexia. ==Causes== Cachexia is most commonly associated with end-stage cancer, often called cancer cachexia. Other conditions that frequently cause cachexia include: Congestive heart failure AIDS Chronic obstructive pulmonary disease Chronic kidney disease Cachexia can happen in late stages of diseases like cystic fibrosis, multiple sclerosis, motor neuron disease, Parkinson's disease, dementia, tuberculosis, multiple system atrophy, mercury poisoning, Crohn's disease, trypanosomiasis, rheumatoid arthritis, celiac disease, and other diseases that affect the entire body. ==Mechanism== The way cachexia works is not well understood, but research suggests the cause is linked to these main processes in the body: inflammation, changes in metabolism, and hormone changes in the body. ==Diagnosis== Doctors formerly diagnosed cachexia mainly by looking at changes in body weight. A person was considered to have cachexia if they had a low BMI or unwanted weight loss of more than 10%. However, weight alone is not always a reliable method. Factors like fluid buildup (edema), tumor size, and obesity can make it difficult to diagnose cachexia. These weight-based criteria do not account for muscle loss, which is a key part in cachexia. . To improve diagnosis of cachexia, experts proposed adding lab tests and symptom evaluations. With that, a person might have cachexia if they lost at least 5% of their total body weight in 12 months or had a BMI under less 22&nbsp;kg/m 2 with at least three of the following: weak muscles, fatigue, loss of appetite, low muscle mass, or abnormal labs. There have been attempts to define specific types of cachexia, such as cardiac cachexia, which can occur in people with congestive heart failure. However, it has no widely accepted definition. ==Treatment== Because cachexia is a complex condition with several potential causes, treatment requires multiple approaches at the same time. The best strategy is to treat the cause of the cachexia, if known. For example, people with cachexia caused by AIDS often improve after starting treatment for AIDS. However, because the exact mechanism of cachexia is unclear, there is no single medication that can effectively treat it. Instead, treatment focuses on a combination of exercise, nutrition, medications like appetite stimulants and androgens like nandrolone decanoate, and psychosocial support. ===Exercise=== Regular physical exercise is recommended for the treatment of cachexia because of its positive effects on muscle function. Exercise can reduce protein breakdown, improve muscle strength, decrease inflammation, and enhance metabolism. However, its effectiveness in cancer patients - especially those who are frail or have sarcopenia - remains uncertain. Many people with cachexia also avoid exercise because they lack motivation or fear that it will worsen their symptoms. ===Nutrition=== Cachexia can increase metabolism and suppress appetite, worsening the present muscle loss. Studies show that high-calorie, protein-rich diets may help stabilize weight, though they do not necessarily improve muscle mass. Recommendations include 1.5g/kg/day of protein, making up 15-20% of daily calories. However, feeding tubes (enteral nutrition) should not be used routinely. ===Medications=== Some medications, such as glucocorticoids, cannabinoids, and progestins were initially used in treating cachexia and aim to increase appetite. Progestins showed promise initially, but they do not stop muscle wasting and may cause fluid retention, fat gain, and other side effects. Ghrelin agonists, such as anamorelin are commonly used in cancer treatment to boost appetite, increase weight, and increase muscle mass. However, its use and effectiveness in cachexia is not well studied. Selective androgen receptor modulators (SARMs) such as enobosarm show promise in increasing physical performance and muscle mass, but more studies are needed to confirm their effectiveness in cachexia. The use of anti-inflammatory medications have been investigated. Thalidomide, an anti-inflammatory agent, has shown promise in preventing weight loss, but the use of this medication in cachexia is not widely accepted. However, other TNF inhibitors have not shown the same promising results. NSAIDs such as celecoxib and ibuprofen showed some early benefits, but side effects (renal injury, GI bleeding) limit their use. Anti-nausea drugs such as 5-HT 3 antagonists are also commonly used if nausea is a prominent symptom. Anabolic steroids like oxandrolone may help but are only recommended for short term use due to side effects including liver toxicity. ==Epidemiology== Accurate epidemiological data on the prevalence of cachexia is lacking due to changing diagnostic criteria and under-identification of people with the disorder. It is estimated that cachexia from any disease is estimated to affect more than 5 million people in the United States. The prevalence of cachexia is growing and estimated at 1% of the population. The prevalence is lower in Asia but due to the larger population, represents a similar burden. Cachexia is also a significant problem in South America and Africa. In people with cancer, prevalence of cachexia was previously reported to range from 11% to 71%. Recent updates show that 33%-51.8% of people with cancer develop cachexia, though estimates vary widely and may be unreliable due to absence of consensus guidelines for diagnosis, variability in cancer populations, and variability in timing of diagnosis. Specifically, the highest rates were seen in older populations as well as those with upper gastrointestinal, colorectal, and lung cancers, respectively. The prevalence increases in advanced cancer stages, affecting up to 80% of terminal cancer cases. The most frequent diseases causing cachexia in the United States are: 1) cancer, 2) chronic heart failure, 3) chronic kidney disease, 4) COPD. Cachexia contributes to significant loss of function and healthcare utilization. Estimates suggest that cachexia accounted for 177,640 hospital stays in 2016 in the United States. Cachexia is considered the immediate cause of death of many people with cancer, estimated between 22 and 40%. ==History== The word \"cachexia\" is derived from the Greek words and . English ophthalmologist John Zachariah Laurence was the first to use the phrase \"cancerous cachexia\", doing so in 1858. He applied the phrase to the chronic wasting associated with malignancy. It was not until 2011 that the term \"cancer-associated cachexia\" was given a formal definition, with a publication by Kenneth Fearon. Fearon defined it as \"a multifactorial syndrome characterized by ongoing loss of skeletal muscle (with or without loss of fat mass) that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment\". ==Research== Several medications are under investigation or have been previously trialed for use in cachexia but are not in widespread clinical use: Thalidomide Cytokine antagonists Cannabinoids Omega-3 fatty acids, including eicosapentaenoic acid (EPA) Non-steroidal anti-inflammatory drugs Prokinetics Ghrelin and ghrelin receptor agonist Anabolic catabolic transforming agents such as MT-102 Selective androgen receptor modulators Cyproheptadine Hydrazine sulfate Medical marijuana has been allowed for the treatment of cachexia in some US states, such as Missouri, Illinois, Maryland, Delaware, Nevada, Michigan, Washington, Oregon, California, Colorado, New Mexico, Arizona, Vermont, New Jersey, Rhode Island, Maine, and New York Hawaii and Connecticut. ===Multimodal therapy=== Despite the extensive investigation into single therapeutic targets for cachexia, the most effective treatments use multi-targeted therapies. In Europe, a combination of non-drug approaches including physical training, nutritional counseling, and psychotherapeutic intervention are used in belief this approach may be more effective than monotherapy. Administration of anti-inflammatory drugs showed efficacy and safety in the treatment of people with advanced cancer cachexia.",
  "categories": [
    "128808146",
    "21493616",
    "22175996",
    "23118434",
    "23603337",
    "24623845",
    "26937525",
    "28374593",
    "33360862",
    "45792122",
    "56905663",
    "66211109",
    "68328988",
    "96369911"
  ],
  "license": "CC BY-SA 4.0",
  "source_uri": "https://en.wikipedia.org/w/index.php?oldid=1376090941",
  "content_hash": "bb04eed9c6d9fc4d19671e84982e41770f68284ebc89ffaff59cafe1ba69853e",
  "created_at": 1792316299.3268936,
  "updated_at": 1790031329.0,
  "claims": [],
  "contradictions": [],
  "confidence": 0.6,
  "csl": {
    "id": "cachexia-1625389-bb04eed9c6d9fc4d",
    "type": "webpage",
    "title": "Cachexia",
    "author": [
      {
        "family": "Anticloud FZ LLE",
        "literal": "Anticloud FZ LLE"
      }
    ],
    "container-title": "encyclopegia.org",
    "publisher": "Anticloud FZ LLE",
    "publisher-place": "Dubai, United Arab Emirates",
    "URL": "https://encyclopegia.org/a/cachexia",
    "issued": {
      "date-parts": [
        [
          2026,
          10,
          18
        ]
      ]
    },
    "accessed": {
      "date-parts": [
        [
          2026,
          11,
          18
        ]
      ]
    },
    "license": "CC BY-SA 4.0",
    "DOI": "eo1:cachexia-1625389-bb04eed9c6d9fc4d",
    "isBasedOn": "https://en.wikipedia.org/w/index.php?oldid=1376090941",
    "note": "Immutable snapshot cachexia-1625389-bb04eed9c6d9fc4d, content root bb04eed9c6d9fc4d…"
  }
}